<DOC>
	<DOCNO>NCT02465437</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , efficacy JBT-101 adult subject diffuse cutaneous systemic sclerosis .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy , Pharmacokinetics JBT-101 Systemic Sclerosis</brief_title>
	<detailed_description>Part A study interventional , double-blind , randomize , placebo-control design use test safety , tolerability , pharmacokinetics , efficacy JBT-101 subject ≥ 18 ≤ 70 year age active diffuse cutaneous systemic sclerosis . The screening period 28 day , 84 day treatment period 28 day follow-up active treatment . Part B study interventional , open-label design use . All subject complete dose Part A without permanent discontinuation study drug pas repeat safety screen eligible enrollment . The screening period 28 day , 364 day treatment period 28 day follow last dose JBT-101 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Part A Diffuse cutaneous systemic sclerosis Have skin thicken SSc body area suitable repeat biopsy Disease duration ≤ 3 year first nonRaynaud 's phenomenon &gt; 3 year ≤ 6 year first nonRaynaud 's phenomenon high sensitivity Creactive protein &gt; 3 mg/L , high sensitivity interleukin6 &gt; 5 pg/mL , increase mRSS ≥ 5 point last 6 month total RSS ≥ 12 . Stable treatment SSc least 28 day Visit 1 Part B •Completion dose Part A without permanent discontinuation study product safety tolerability reason . Exclusion Criteria ( Part A B ) : Severe unstable systemic sclerosis Significant diseases condition systemic sclerosis may influence response study product safety ; Any one following value laboratory test Screening : 1 . A positive pregnancy test ( Visit 1 ) ; 2 . Hemoglobin &lt; 10 g/dL 3 . Neutrophils &lt; 1.0 x 10^9/L 4 . Platelets &lt; 75 x 10^9/L 5 . Creatinine clearance &lt; 50 ml/min accord modify CockcroftGault equation 6 . Serum transaminases &gt; 2.0 x upper normal limit 7 . Total bilirubin ≥ 1.5 x upper limit normal Any condition , opinion Principal Investigator , clinically significant may put subject great safety risk , influence response study product , interfere study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>